메뉴 건너뛰기




Volumn 83, Issue 4, 2012, Pages 1192-1197

Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies

Author keywords

Bortezomib; Chemoradiotherapy; Head and neck cancer; Proteasome inhibitors

Indexed keywords

BORTEZOMIB; CIS-PLATIN; CONCURRENT CHEMORADIOTHERAPY; DOSE ESCALATION; DOSE LEVELS; DOSE LIMITING TOXICITY; DOSE-ESCALATION STUDY; HEAD-AND-NECK CANCER; MAXIMUM TOLERATED DOSE; MEDIAN SURVIVAL; PHASE I; PROTEASOME INHIBITORS;

EID: 84862640499     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.09.023     Document Type: Article
Times cited : (28)

References (18)
  • 1
    • 36049015455 scopus 로고    scopus 로고
    • Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of Radiation Therapy Oncology Group Protocol 9911
    • Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007;25:4800-4805.
    • (2007) J Clin Oncol , vol.25 , pp. 4800-4805
    • Langer, C.J.1    Harris, J.2    Horwitz, E.M.3
  • 2
    • 0033017066 scopus 로고    scopus 로고
    • Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer
    • Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-1379.
    • (1999) Clin Cancer Res , vol.5 , pp. 1369-1379
    • Chen, Z.1    Malhotra, P.S.2    Thomas, G.R.3
  • 3
    • 0035529049 scopus 로고    scopus 로고
    • Constitutive NFkappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines
    • Didelot C, Barberi-Heyob M, Bianchi A, et al. Constitutive NFkappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines. Int J Radiat Oncol Biol Phys 2001;51:1354-1360.
    • (2001) Int J Radiat Oncol Biol Phys , vol.51 , pp. 1354-1360
    • Didelot, C.1    Barberi-Heyob, M.2    Bianchi, A.3
  • 4
    • 35348918435 scopus 로고    scopus 로고
    • A novel NF-kB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status
    • Lee TL, Yang XP, Yan B, et al. A novel NF-kB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007;13:5680-5691.
    • (2007) Clin Cancer Res , vol.13 , pp. 5680-5691
    • Lee, T.L.1    Yang, X.P.2    Yan, B.3
  • 5
    • 20444433230 scopus 로고    scopus 로고
    • Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    • Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
    • (2005) N Engl J Med , vol.352 , pp. 2487-2498
    • Richardson, P.G.1    Sonneveld, P.2    Schuster, M.W.3
  • 6
    • 7644242953 scopus 로고    scopus 로고
    • Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
    • Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-9704.
    • (2004) Mol Cell Biol , vol.24 , pp. 9695-9704
    • Fribley, A.1    Zeng, Q.2    Wang, C.Y.3
  • 7
    • 34247390711 scopus 로고    scopus 로고
    • Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation
    • Weber CN, Cerniglia GJ, Maity A, et al. Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol Ther 2007;6:156-159.
    • (2007) Cancer Biol Ther , vol.6 , pp. 156-159
    • Weber, C.N.1    Cerniglia, G.J.2    Maity, A.3
  • 8
    • 27744515028 scopus 로고    scopus 로고
    • Inhibition of nuclear factor-kb and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
    • Waes CV, Chang AA, Lebowitz PF. Inhibition of nuclear factor-kb and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63: 1400-1412.
    • (2005) Int J Radiat Oncol Biol Phys , vol.63 , pp. 1400-1412
    • Waes, C.V.1    Chang, A.A.2    Lebowitz, P.F.3
  • 9
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 10
    • 50449086728 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    • San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
    • (2008) N Engl J Med , vol.359 , pp. 906-917
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 11
    • 34247855046 scopus 로고    scopus 로고
    • Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial (S0327)
    • Lara PN Jr., Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006;9:996-1001.
    • (2006) J Thorac Oncol , vol.9 , pp. 996-1001
    • Lara Jr., P.N.1    Chansky, K.2    Davies, A.M.3
  • 12
    • 33750945704 scopus 로고    scopus 로고
    • Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
    • Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-5033.
    • (2006) J Clin Oncol , vol.24 , pp. 5025-5033
    • Fanucchi, M.P.1    Fossella, F.V.2    Belt, R.3
  • 13
    • 33751563004 scopus 로고    scopus 로고
    • A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
    • Ryan DP, O'Neil BH, Supko JG, et al. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006; 107:2688-2697.
    • (2006) Cancer , vol.107 , pp. 2688-2697
    • Ryan, D.P.1    O'Neil, B.H.2    Supko, J.G.3
  • 14
    • 67349138194 scopus 로고    scopus 로고
    • Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies
    • Kubicek GJ, Werner-Wasik M, Machtay M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009;74:433-439.
    • (2009) Int J Radiat Oncol Biol Phys , vol.74 , pp. 433-439
    • Kubicek, G.J.1    Werner-Wasik, M.2    Machtay, M.3
  • 15
    • 79951716964 scopus 로고    scopus 로고
    • Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies
    • Pugh TJ, Chen C, Rabinovitch R, et al. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys 2010;78:521-526.
    • (2010) Int J Radiat Oncol Biol Phys , vol.78 , pp. 521-526
    • Pugh, T.J.1    Chen, C.2    Rabinovitch, R.3
  • 16
    • 33750976204 scopus 로고    scopus 로고
    • Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
    • Ryan DP, Appleman LJ, Lynch T, et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006;107:2482-2489.
    • (2006) Cancer , vol.107 , pp. 2482-2489
    • Ryan, D.P.1    Appleman, L.J.2    Lynch, T.3
  • 17
    • 61549138750 scopus 로고    scopus 로고
    • Bortezomib plus gemcitabine/ carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group Study (S0339)
    • Davies AM, Chansky K, Lara PN, et al. Bortezomib plus gemcitabine/ carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009;4:87-92.
    • (2009) J Thorac Oncol , vol.4 , pp. 87-92
    • Davies, A.M.1    Chansky, K.2    Lara, P.N.3
  • 18
    • 33846685893 scopus 로고    scopus 로고
    • Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer
    • Lorch JH, Thomas TO, Schmoll HJ. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 2007;67:727-734.
    • (2007) Cancer Res , vol.67 , pp. 727-734
    • Lorch, J.H.1    Thomas, T.O.2    Schmoll, H.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.